Department of Immunology, Affiliated Cancer Hospital of Zhengzhou University and Henan Cancer Hospital, Zhengzhou, Henan 450008, China.
Department of Hematology, Affiliated Cancer Hospital of Zhengzhou University and Henan Cancer Hospital, Zhengzhou, Henan 450008, China.
J Immunol Res. 2016;2016:5706814. doi: 10.1155/2016/5706814. Epub 2016 Jun 28.
Adoptive cell therapy (ACT) using autologous cytokine-induced killer (CIK) cells is a promising treatment for metastatic carcinomas. In this study, we investigated the impact of RetroNectin on the proliferation, phenotype alternation, cytokine secretion, and cytotoxic activity of CIK cells from pancreatic cancer patients. Furthermore, we treated 13 patients with metastatic or locally advanced pancreatic cancer using autologous RetroNectin-activated CIK cells (R-CIK cells) alone or in combination with chemotherapy. Compared with only CD3 activated CIK cells (OKT-CIK cells), R-CIK cells showed stronger and faster proliferative ability, with a lower ratio of spontaneous apoptosis. Moreover, this ability continued after IL-2 was withdrawn from the culture system. R-CIK cells could also secrete higher levels of IL-2 and lower levels of IL-4 and IL-5 versus OKT-CIK cells. There was no difference between OKT-CIK and R-CIK cells in cytotoxic ability against lymphoma cell line K562. In patients who received auto-R-CIK cell infusion therapy, the overall objective response rate was 23.1%. Median survival time (mOS) after first R-CIK cell infusion was 10.57 months; the 1-year survival rate was 38.5%. No serious toxicity was associated with R-CIK cell infusion. In conclusion, RetroNectin may enhance antitumor activity of CIK cells: it is safe for use in treating pancreatic cancer.
过继细胞疗法（ACT）使用自体细胞因子诱导的杀伤（CIK）细胞是治疗转移性癌的一种很有前途的方法。在这项研究中，我们研究了 RetroNectin 对胰腺癌患者 CIK 细胞增殖、表型改变、细胞因子分泌和细胞毒性活性的影响。此外，我们使用自体 RetroNectin 激活的 CIK 细胞（R-CIK 细胞）单独或与化疗联合治疗了 13 名转移性或局部晚期胰腺癌患者。与仅 CD3 激活的 CIK 细胞（OKT-CIK 细胞）相比，R-CIK 细胞显示出更强和更快的增殖能力，自发凋亡比例更低。此外，这种能力在培养系统中去除 IL-2 后仍能持续。R-CIK 细胞还可以分泌更高水平的 IL-2 和更低水平的 IL-4 和 IL-5，与 OKT-CIK 细胞相比。OKT-CIK 和 R-CIK 细胞对淋巴瘤细胞系 K562 的细胞毒性能力没有差异。在接受自体 R-CIK 细胞输注治疗的患者中，总客观缓解率为 23.1%。首次输注 R-CIK 细胞后中位生存时间（mOS）为 10.57 个月；1 年生存率为 38.5%。R-CIK 细胞输注无严重毒性。总之，RetroNectin 可能增强 CIK 细胞的抗肿瘤活性：它安全用于治疗胰腺癌。
